CN114539422A - 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 - Google Patents
核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 Download PDFInfo
- Publication number
- CN114539422A CN114539422A CN202011340377.3A CN202011340377A CN114539422A CN 114539422 A CN114539422 A CN 114539422A CN 202011340377 A CN202011340377 A CN 202011340377A CN 114539422 A CN114539422 A CN 114539422A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- sequence
- pairing
- free energy
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 222
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 79
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title abstract description 61
- 229940079593 drug Drugs 0.000 title abstract description 58
- 102000004169 proteins and genes Human genes 0.000 title abstract description 52
- 108090000623 proteins and genes Proteins 0.000 title abstract description 52
- 229960005486 vaccine Drugs 0.000 title abstract description 12
- 238000010276 construction Methods 0.000 title abstract description 4
- 230000001404 mediated effect Effects 0.000 title abstract description 4
- 238000006116 polymerization reaction Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000178 monomer Substances 0.000 claims abstract description 24
- 229920000642 polymer Polymers 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 72
- 238000000137 annealing Methods 0.000 claims description 61
- 238000005457 optimization Methods 0.000 claims description 54
- 230000000295 complement effect Effects 0.000 claims description 38
- 238000010494 dissociation reaction Methods 0.000 claims description 34
- 230000005593 dissociations Effects 0.000 claims description 34
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 230000010354 integration Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims 1
- 108091007433 antigens Proteins 0.000 abstract description 46
- 102000036639 antigens Human genes 0.000 abstract description 46
- 239000000427 antigen Substances 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 26
- 102000037865 fusion proteins Human genes 0.000 abstract description 8
- 108020001507 fusion proteins Proteins 0.000 abstract description 8
- 230000005847 immunogenicity Effects 0.000 abstract description 5
- 238000004132 cross linking Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 14
- 230000009466 transformation Effects 0.000 description 14
- 125000005647 linker group Chemical group 0.000 description 12
- 239000013638 trimer Substances 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- -1 5-hydroxymethyl cytosine nucleic acid Chemical class 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000002922 simulated annealing Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001338 self-assembly Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091008875 B cell receptors Proteins 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000012804 iterative process Methods 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-hydroxymethylcytosine Natural products NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- IBYAOODMUFJKEW-UHFFFAOYSA-N dihydrogen phosphate;morpholin-4-ium Chemical class OP(O)(O)=O.C1COCCN1 IBYAOODMUFJKEW-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/10—Nucleic acid folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physiology (AREA)
Abstract
Description
序列编号 | 初始化序列 | SEQ ID No: |
S<sub>1</sub> | <u>A</u>GTGATCCGAAGTCGAC<u>AAA</u>CGTATTAGCGCTCGAT | <u>241</u> |
S<sub>2</sub> | <u>A</u>ATCGAGCGCTAATACG<u>AAA</u>GTGCAATGCGTCGATG | <u>242</u> |
S<sub>3</sub> | <u>A</u>CATCGACGCATTGCAC<u>AAA</u>GTCGACTTCGGATCAC | <u>243</u> |
序列编号 | 优化后序列 | |
S<sub>1</sub> | <u>A</u>CCACCGTGTATGACCT<u>AAA</u>AGTGACAGCACATCGC | 244 |
S<sub>2</sub> | <u>A</u>GCGATGTGCTGTCACT<u>AAA</u>ACAGGCTCTACGAGGA | 245 |
S<sub>3</sub> | <u>A</u>TCCTCGTAGAGCCTGT<u>AAA</u>AGGTCATACACGGTGG | <u>246</u> |
S<sub>1</sub> | X1-Q1-AATCC-X2-TGAGC-Q2-X3 |
S<sub>2</sub> | X1-Q3-GCTCA-X2-CCGAA-Q4-X3 |
S<sub>3</sub> | X1-Q5-TTCGG-X2-ACTAT-Q6-X3 |
S<sub>4</sub> | X1-Q7-ATAGT-X2-GGATT-Q8-X3 |
序列编号 | 初始化序列 | SEQ ID No: |
S<sub>1</sub> | <u>A</u>ACCTGGTACAATCC<u>AAA</u>TGAGCTACACTAGC | <u>247</u> |
S<sub>2</sub> | <u>A</u>GCTAGTGTAGCTCA<u>AAA</u>CCGAAGTATCGATT | <u>248</u> |
S<sub>3</sub> | <u>A</u>AATCGATACTTCGG<u>AAA</u>ACTATAGTGAGTTG | 249 |
S<sub>4</sub> | <u>A</u>CAACTCACTATAGT<u>AAA</u>GGATTGTACCAGGT | <u>250</u> |
序列编号 | 优化后序列 | |
S<sub>1</sub> | <u>A</u>GGCGATCACAATCC<u>AAA</u>TGAGCGTGTTACGG | <u>251</u> |
S<sub>2</sub> | <u>A</u>CCGTAACACGCTCA<u>AAA</u>CCGAAGTGCCAATT | <u>252</u> |
S<sub>3</sub> | <u>A</u>AATTGGCACTTCGG<u>AAA</u>ACTATGCGGCTGCT | <u>253</u> |
S<sub>4</sub> | <u>A</u>AGCAGCCGCATAGT<u>AAA</u>GGATTGTGATCGCC | <u>254</u> |
S<sub>1</sub> | X1-R9-X2-R10-X3 |
S<sub>2</sub> | X1-R1-X2-AATCC-X2-TGAGC-Q1-X3 |
S<sub>3</sub> | X1-Q2-GCTCA-X2-CCGAA-Q3-X3 |
S<sub>4</sub> | X1-Q4-TTCGG-X2-ACTAT-Q5-X3 |
S<sub>5</sub> | X1-Q6-ATAGT-X2-GGATT-X2-R8-X3 |
序列编号 | 初始化序列 | SEQ ID No: |
S<sub>1</sub> | <u>A</u>TCACAGAGCGCGTA<u>AAA</u>ACGCCACTCATGGA | 255 |
S<sub>2</sub> | <u>A</u>TCCATGAGTGGCGT<u>AAA</u>AATCC<u>AAA</u>TGAGCGTGTTACGG | 256 |
S<sub>3</sub> | ACCGTAACACGCTCA<u>AAA</u>CCGAAGTGCCAATT | 257 |
S<sub>4</sub> | <u>A</u>AATTGGCACTTCGG<u>AAA</u>ACTATGCGGCTGCT | 258 |
S<sub>5</sub> | <u>A</u>AGCAGCCGCATAGT<u>AAA</u>GGATT<u>AAA</u>TACGCGCTCTGTGA | 259 |
序列编号 | 优化后序列 | |
S<sub>1</sub> | <u>A</u>TTCAGGCGACTCCT<u>AAA</u>AGCACGACGATGGT | 260 |
S<sub>2</sub> | <u>A</u>ACCATCGTCGTGCT<u>AAA</u>AATCC<u>AAA</u>TGAGCGTGTTACGG | 261 |
S<sub>3</sub> | <u>A</u>CCGTAACACGCTCA<u>AAA</u>CCGAAGTGCCAATT | 262 |
S<sub>4</sub> | <u>A</u>AATTGGCACTTCGG<u>AAA</u>ACTATGCGGCTGCT | 263 |
S<sub>5</sub> | <u>A</u>AGCAGCCGCATAGT<u>AAA</u>GGATT<u>AAA</u>AGGAGTCGCCTGAA | 264 |
S<sub>1</sub> | X1-Q1-AATCC-X2-R10-X3 |
S<sub>2</sub> | X1-R2-X2-TGAGC-Q2-X3 |
S<sub>3</sub> | X1-Q3-GCTCA-X2-CCGAA-Q4-X3 |
S<sub>4</sub> | X1-Q5-TTCGG-X2-ACTAT-Q6-X3 |
S<sub>5</sub> | X1-Q7-ATAGT-X2-GGATT-Q8-X3 |
序列编号 | 初始化序列 | SEQ ID No: |
S<sub>1</sub> | <u>A</u>TGAGTGCGCAATCC<u>AAA</u>TCGCCAGTCATGCA | 265 |
S<sub>2</sub> | <u>A</u>TGCATGACTGGCGA<u>AAA</u>TGAGCGCTCGTTGA | 266 |
S<sub>3</sub> | <u>A</u>TCAACGAGCGCTCA<u>AAA</u>CCGAAGTGCCAACT | 267 |
S<sub>4</sub> | <u>A</u>AGTTGGCACTTCGG<u>AAA</u>ACTATCGCGCGACT | 268 |
S<sub>5</sub> | <u>A</u>AGTCGCGCGATAGT<u>AAA</u>GGATTGCGCACTCA | 269 |
序列编号 | 优化后序列 | |
S<sub>1</sub> | <u>A</u>TCACGCAGCAATCC<u>AAA</u>TCGCCATCACAACG | 270 |
S<sub>2</sub> | <u>A</u>CGTTGTGATGGCGA<u>AAA</u>TGAGCACGAGCCTT | 271 |
S<sub>3</sub> | <u>A</u>AAGGCTCGTGCTCA<u>AAA</u>CCGAAGGTTGCACT | 272 |
S<sub>4</sub> | <u>A</u>AGTGCAACCTTCGG<u>AAA</u>ACTATGCCGCTCCA | 273 |
S<sub>5</sub> | <u>A</u>TGGAGCGGCATAGT<u>AAA</u>GGATTGCTGCGTGA | 274 |
Claims (10)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011340377.3A CN114539422B (zh) | 2020-11-25 | 2020-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
CN202180079161.2A CN116600823A (zh) | 2020-11-25 | 2021-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
CA3200188A CA3200188A1 (en) | 2020-11-25 | 2021-11-25 | Construction method for and application of nucleic acid multimerization-mediated multivalent protein drug and vaccine |
KR1020237021280A KR20230123972A (ko) | 2020-11-25 | 2021-11-25 | 핵산 다량체화-매개된 다가 단백질 약물 및 백신의 제조 방법 및 용도 |
JP2023532213A JP2023551827A (ja) | 2020-11-25 | 2021-11-25 | 核酸多量化を介した多価タンパク質薬物およびワクチンの構築方法と適用 |
EP21897098.6A EP4253609A1 (en) | 2020-11-25 | 2021-11-25 | Construction method for and application of nucleic acid multimerization-mediated multivalent protein drug and vaccine |
PCT/CN2021/133254 WO2022111598A1 (zh) | 2020-11-25 | 2021-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
AU2021390000A AU2021390000A1 (en) | 2020-11-25 | 2021-11-25 | Construction method for and application of nucleic acid multimerization-mediated multivalent protein drug and vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011340377.3A CN114539422B (zh) | 2020-11-25 | 2020-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114539422A true CN114539422A (zh) | 2022-05-27 |
CN114539422B CN114539422B (zh) | 2024-03-29 |
Family
ID=81659911
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011340377.3A Active CN114539422B (zh) | 2020-11-25 | 2020-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
CN202180079161.2A Pending CN116600823A (zh) | 2020-11-25 | 2021-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180079161.2A Pending CN116600823A (zh) | 2020-11-25 | 2021-11-25 | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4253609A1 (zh) |
JP (1) | JP2023551827A (zh) |
KR (1) | KR20230123972A (zh) |
CN (2) | CN114539422B (zh) |
AU (1) | AU2021390000A1 (zh) |
CA (1) | CA3200188A1 (zh) |
WO (1) | WO2022111598A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000665A1 (en) * | 1993-06-17 | 1995-01-05 | The Research Foundation Of State University Of New York | Thermodynamics, design, and use of nucleic acid sequences |
US5561043A (en) * | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US20030027194A1 (en) * | 2001-07-31 | 2003-02-06 | Markus Kurz | Modular assembly of nucleic acid-protein fusion multimers |
US20030118595A1 (en) * | 1994-01-31 | 2003-06-26 | Christof M. Niemeyer | Supramolecular bioconjugates |
CN1533441A (zh) * | 2001-06-20 | 2004-09-29 | ղ��� | 核酸三链体和四链体形成 |
WO2009057702A1 (ja) * | 2007-10-31 | 2009-05-07 | Eisai R & D Management Co., Ltd. | 標的物質検出用ポリマー及び標的物質の検出方法 |
WO2018205755A1 (zh) * | 2017-05-09 | 2018-11-15 | 安升(上海)医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
CN101866388B (zh) * | 2009-04-16 | 2012-07-04 | 北京大学 | 一种dna计算编码系统及其方法 |
CN112746331A (zh) * | 2019-10-29 | 2021-05-04 | 安升(上海)医药科技有限公司 | 半衰期延长的药物及其文库、以及制备方法和应用 |
-
2020
- 2020-11-25 CN CN202011340377.3A patent/CN114539422B/zh active Active
-
2021
- 2021-11-25 EP EP21897098.6A patent/EP4253609A1/en active Pending
- 2021-11-25 CA CA3200188A patent/CA3200188A1/en active Pending
- 2021-11-25 CN CN202180079161.2A patent/CN116600823A/zh active Pending
- 2021-11-25 KR KR1020237021280A patent/KR20230123972A/ko active Search and Examination
- 2021-11-25 JP JP2023532213A patent/JP2023551827A/ja active Pending
- 2021-11-25 AU AU2021390000A patent/AU2021390000A1/en active Pending
- 2021-11-25 WO PCT/CN2021/133254 patent/WO2022111598A1/zh active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000665A1 (en) * | 1993-06-17 | 1995-01-05 | The Research Foundation Of State University Of New York | Thermodynamics, design, and use of nucleic acid sequences |
US5561043A (en) * | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US20030118595A1 (en) * | 1994-01-31 | 2003-06-26 | Christof M. Niemeyer | Supramolecular bioconjugates |
CN1533441A (zh) * | 2001-06-20 | 2004-09-29 | ղ��� | 核酸三链体和四链体形成 |
US20030027194A1 (en) * | 2001-07-31 | 2003-02-06 | Markus Kurz | Modular assembly of nucleic acid-protein fusion multimers |
WO2009057702A1 (ja) * | 2007-10-31 | 2009-05-07 | Eisai R & D Management Co., Ltd. | 標的物質検出用ポリマー及び標的物質の検出方法 |
US20110171639A1 (en) * | 2007-10-31 | 2011-07-14 | Eisai R&D Management Co., Ltd. | Polymer for detection of target substance, and method for detection of target substance |
WO2018205755A1 (zh) * | 2017-05-09 | 2018-11-15 | 安升(上海)医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
Non-Patent Citations (5)
Title |
---|
刘文斌,王淑栋,许进: "DNA计算中的编码方法研究" * |
吕鸣;张晓东;潘家奎;张治洲;胡钧;: "一种基于关键路径法的DNA计算用寡核苷酸序列设计算法" * |
崔光照;周君和;王延峰;: "DNA计算中的编码序列设计问题" * |
崔光照;张勋才;王延峰;: "DNA计算中编码序列的优化设计方案" * |
张凯等: "基于多目标进化策略算法的DNA核酸编码设计" * |
Also Published As
Publication number | Publication date |
---|---|
CN114539422B (zh) | 2024-03-29 |
AU2021390000A1 (en) | 2023-06-29 |
AU2021390000A9 (en) | 2023-08-17 |
WO2022111598A1 (zh) | 2022-06-02 |
CA3200188A1 (en) | 2022-06-02 |
EP4253609A1 (en) | 2023-10-04 |
CN116600823A (zh) | 2023-08-15 |
JP2023551827A (ja) | 2023-12-13 |
KR20230123972A (ko) | 2023-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ni et al. | Recent progress in aptamer discoveries and modifications for therapeutic applications | |
AU775076B2 (en) | Protein scaffolds for antibody mimics and other binding proteins | |
CA2064689C (en) | Stabilized protein or peptide conjugates | |
JP6893505B2 (ja) | オリゴヌクレオチドコンジュゲーション方法 | |
US20070248536A1 (en) | Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography | |
CN107889503A (zh) | 固定化的聚(n)聚合酶 | |
JP2002325594A (ja) | 組換えdna技術によってdna、rna、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法 | |
KR102237130B1 (ko) | 향상된 특성을 갖는 변형된 코일드 코일 유형 단백질 | |
Craig et al. | Polymeric display of proteins through high affinity leucine zipper peptide adaptors | |
CN114539422A (zh) | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 | |
RU2564855C2 (ru) | Способ получения пэгилированных олигонуклеотидов | |
US20220370626A1 (en) | FN3 Domain-siRNA Conjugates and Uses Thereof | |
CN107108691A (zh) | 蛋白质制造方法 | |
JP2016163565A (ja) | 抗体特異性をリダイレクトするための高親和性アダプター分子 | |
CN114075282B (zh) | Il-5的结合分子及其制备方法和应用 | |
CN111057154B (zh) | 基于驼源Fc片段的免疫原的制备及应用 | |
US20230132627A1 (en) | Oligonucleotides and methods for preparing | |
JP2023501020A (ja) | 治療用分子の標的化送達 | |
JP2004261024A (ja) | ペプチド修飾多糖類を用いる遺伝子治療剤 | |
CN117070514A (zh) | 非天然rna的制备方法及产品 | |
AU782856B2 (en) | Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules | |
CN117615790A (zh) | FN3结构域-siRNA缀合物及其用途 | |
CN117106681A (zh) | 能够稳定表达抗原多糖-蛋白生物偶联相关生物元件并提高产物产量的工程菌及其应用 | |
WO2023201362A2 (en) | Fn3 domain-sirna conjugates with enzyme replacement therapy | |
CN103374569B (zh) | 在仓鼠细胞中的重复位点处进行定点重组的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40074057 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: 201203 Floor 2-3, Building 1, No. 88 Darwin Road, Pudong New Area, Shanghai Applicant after: ANSHENG (SHANGHAI) MEDICINE TECHNOLOGY Co.,Ltd. Address before: Room 1107, No. 781 Cailun Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai, 201203 Applicant before: ANSHENG (SHANGHAI) MEDICINE TECHNOLOGY Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |